Click for best price
Cancer Generics Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Cancer Generics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Generics. This report contains market size and forecasts of Cancer Generics in global, including the following market information:
The global Cancer Generics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Chemotherapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cancer Generics include Teva Pharmaceuticals, Pfizer, Accord Healthcare, Amneal Pharmaceuticals, Mylan, DrReddy Laboratories, Bedford Pharma, Hikma and Cipla, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Generics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Generics Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Cancer Generics Market Segment Percentages, by Type, 2022 (%)
- Chemotherapy
- Biological Targeted Therapy Drugs
- Prescription Drugs
- Chinese Patent Medicine
- Other
Global Cancer Generics Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Cancer Generics Market Segment Percentages, by Application, 2022 (%)
- Hospital
- Clinic
- Drug Center
- Other
Global Cancer Generics Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Cancer Generics Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Cancer Generics revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Cancer Generics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Teva Pharmaceuticals
- Pfizer
- Accord Healthcare
- Amneal Pharmaceuticals
- Mylan
- DrReddy Laboratories
- Bedford Pharma
- Hikma
- Cipla
- Shilpa Medicare
- Fresenius Kabi
- Zydus Pharmaceuticals
- Neopharm
- Netco
- Mayne Pharma
- Alvogen
- Glenmark
- HBT Labs
- Gland
- Qilu Pharmaceuticals
- Akorn Pharmaceuticals
- MSN Group
- Wockhardt
- Rising Pharma
- Apotex
- Taro Pharmaceuticals
- Sun Pharma
- Alkem Laboratories
- Endo Pharma
- Outline of Major Chapters:
- Chapter 1: Introduces the definition of Cancer Generics, market overview.
- Chapter 2: Global Cancer Generics market size in revenue.
- Chapter 3: Detailed analysis of Cancer Generics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Cancer Generics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Cancer Generics Market, Global Outlook and Forecast 2023-2032 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
117 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Cancer Generics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Generics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Generics Overall Market Size
2.1 Global Cancer Generics Market Size: 2022 VS 2032
2.2 Global Cancer Generics Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Cancer Generics Players in Global Market
3.2 Top Global Cancer Generics Companies Ranked by Revenue
3.3 Global Cancer Generics Revenue by Companies
3.4 Top 3 and Top 5 Cancer Generics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Cancer Generics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cancer Generics Players in Global Market
3.6.1 List of Global Tier 1 Cancer Generics Companies
3.6.2 List of Global Tier 2 and Tier 3 Cancer Generics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Cancer Generics Market Size Markets, 2022 & 2032
4.1.2 Chemotherapy
4.1.3 Biological Targeted Therapy Drugs
4.1.4 Prescription Drugs
4.1.5 Chinese Patent Medicine
4.1.6 Other
4.2 By Type - Global Cancer Generics Revenue & Forecasts
4.2.1 By Type - Global Cancer Generics Revenue, 2018-2023
4.2.2 By Type - Global Cancer Generics Revenue, 2024-2032
4.2.3 By Type - Global Cancer Generics Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Cancer Generics Market Size, 2022 & 2032
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Drug Center
5.1.5 Other
5.2 By Application - Global Cancer Generics Revenue & Forecasts
5.2.1 By Application - Global Cancer Generics Revenue, 2018-2023
5.2.2 By Application - Global Cancer Generics Revenue, 2024-2032
5.2.3 By Application - Global Cancer Generics Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Cancer Generics Market Size, 2022 & 2032
6.2 By Region - Global Cancer Generics Revenue & Forecasts
6.2.1 By Region - Global Cancer Generics Revenue, 2018-2023
6.2.2 By Region - Global Cancer Generics Revenue, 2024-2032
6.2.3 By Region - Global Cancer Generics Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Cancer Generics Revenue, 2018-2032
6.3.2 US Cancer Generics Market Size, 2018-2032
6.3.3 Canada Cancer Generics Market Size, 2018-2032
6.3.4 Mexico Cancer Generics Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Cancer Generics Revenue, 2018-2032
6.4.2 Germany Cancer Generics Market Size, 2018-2032
6.4.3 France Cancer Generics Market Size, 2018-2032
6.4.4 U.K. Cancer Generics Market Size, 2018-2032
6.4.5 Italy Cancer Generics Market Size, 2018-2032
6.4.6 Russia Cancer Generics Market Size, 2018-2032
6.4.7 Nordic Countries Cancer Generics Market Size, 2018-2032
6.4.8 Benelux Cancer Generics Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Cancer Generics Revenue, 2018-2032
6.5.2 China Cancer Generics Market Size, 2018-2032
6.5.3 Japan Cancer Generics Market Size, 2018-2032
6.5.4 South Korea Cancer Generics Market Size, 2018-2032
6.5.5 Southeast Asia Cancer Generics Market Size, 2018-2032
6.5.6 India Cancer Generics Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Cancer Generics Revenue, 2018-2032
6.6.2 Brazil Cancer Generics Market Size, 2018-2032
6.6.3 Argentina Cancer Generics Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Cancer Generics Revenue, 2018-2032
6.7.2 Turkey Cancer Generics Market Size, 2018-2032
6.7.3 Israel Cancer Generics Market Size, 2018-2032
6.7.4 Saudi Arabia Cancer Generics Market Size, 2018-2032
6.7.5 UAE Cancer Generics Market Size, 2018-2032
7 Cancer Generics Companies Profiles
7.1 Teva Pharmaceuticals
7.1.1 Teva Pharmaceuticals Company Summary
7.1.2 Teva Pharmaceuticals Business Overview
7.1.3 Teva Pharmaceuticals Cancer Generics Major Product Offerings
7.1.4 Teva Pharmaceuticals Cancer Generics Revenue in Global Market (2018-2023)
7.1.5 Teva Pharmaceuticals Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Cancer Generics Major Product Offerings
7.2.4 Pfizer Cancer Generics Revenue in Global Market (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Accord Healthcare
7.3.1 Accord Healthcare Company Summary
7.3.2 Accord Healthcare Business Overview
7.3.3 Accord Healthcare Cancer Generics Major Product Offerings
7.3.4 Accord Healthcare Cancer Generics Revenue in Global Market (2018-2023)
7.3.5 Accord Healthcare Key News & Latest Developments
7.4 Amneal Pharmaceuticals
7.4.1 Amneal Pharmaceuticals Company Summary
7.4.2 Amneal Pharmaceuticals Business Overview
7.4.3 Amneal Pharmaceuticals Cancer Generics Major Product Offerings
7.4.4 Amneal Pharmaceuticals Cancer Generics Revenue in Global Market (2018-2023)
7.4.5 Amneal Pharmaceuticals Key News & Latest Developments
7.5 Mylan
7.5.1 Mylan Company Summary
7.5.2 Mylan Business Overview
7.5.3 Mylan Cancer Generics Major Product Offerings
7.5.4 Mylan Cancer Generics Revenue in Global Market (2018-2023)
7.5.5 Mylan Key News & Latest Developments
7.6 DrReddy Laboratories
7.6.1 DrReddy Laboratories Company Summary
7.6.2 DrReddy Laboratories Business Overview
7.6.3 DrReddy Laboratories Cancer Generics Major Product Offerings
7.6.4 DrReddy Laboratories Cancer Generics Revenue in Global Market (2018-2023)
7.6.5 DrReddy Laboratories Key News & Latest Developments
7.7 Bedford Pharma
7.7.1 Bedford Pharma Company Summary
7.7.2 Bedford Pharma Business Overview
7.7.3 Bedford Pharma Cancer Generics Major Product Offerings
7.7.4 Bedford Pharma Cancer Generics Revenue in Global Market (2018-2023)
7.7.5 Bedford Pharma Key News & Latest Developments
7.8 Hikma
7.8.1 Hikma Company Summary
7.8.2 Hikma Business Overview
7.8.3 Hikma Cancer Generics Major Product Offerings
7.8.4 Hikma Cancer Generics Revenue in Global Market (2018-2023)
7.8.5 Hikma Key News & Latest Developments
7.9 Cipla
7.9.1 Cipla Company Summary
7.9.2 Cipla Business Overview
7.9.3 Cipla Cancer Generics Major Product Offerings
7.9.4 Cipla Cancer Generics Revenue in Global Market (2018-2023)
7.9.5 Cipla Key News & Latest Developments
7.10 Shilpa Medicare
7.10.1 Shilpa Medicare Company Summary
7.10.2 Shilpa Medicare Business Overview
7.10.3 Shilpa Medicare Cancer Generics Major Product Offerings
7.10.4 Shilpa Medicare Cancer Generics Revenue in Global Market (2018-2023)
7.10.5 Shilpa Medicare Key News & Latest Developments
7.11 Fresenius Kabi
7.11.1 Fresenius Kabi Company Summary
7.11.2 Fresenius Kabi Business Overview
7.11.3 Fresenius Kabi Cancer Generics Major Product Offerings
7.11.4 Fresenius Kabi Cancer Generics Revenue in Global Market (2018-2023)
7.11.5 Fresenius Kabi Key News & Latest Developments
7.12 Zydus Pharmaceuticals
7.12.1 Zydus Pharmaceuticals Company Summary
7.12.2 Zydus Pharmaceuticals Business Overview
7.12.3 Zydus Pharmaceuticals Cancer Generics Major Product Offerings
7.12.4 Zydus Pharmaceuticals Cancer Generics Revenue in Global Market (2018-2023)
7.12.5 Zydus Pharmaceuticals Key News & Latest Developments
7.13 Neopharm
7.13.1 Neopharm Company Summary
7.13.2 Neopharm Business Overview
7.13.3 Neopharm Cancer Generics Major Product Offerings
7.13.4 Neopharm Cancer Generics Revenue in Global Market (2018-2023)
7.13.5 Neopharm Key News & Latest Developments
7.14 Netco
7.14.1 Netco Company Summary
7.14.2 Netco Business Overview
7.14.3 Netco Cancer Generics Major Product Offerings
7.14.4 Netco Cancer Generics Revenue in Global Market (2018-2023)
7.14.5 Netco Key News & Latest Developments
7.15 Mayne Pharma
7.15.1 Mayne Pharma Company Summary
7.15.2 Mayne Pharma Business Overview
7.15.3 Mayne Pharma Cancer Generics Major Product Offerings
7.15.4 Mayne Pharma Cancer Generics Revenue in Global Market (2018-2023)
7.15.5 Mayne Pharma Key News & Latest Developments
7.16 Alvogen
7.16.1 Alvogen Company Summary
7.16.2 Alvogen Business Overview
7.16.3 Alvogen Cancer Generics Major Product Offerings
7.16.4 Alvogen Cancer Generics Revenue in Global Market (2018-2023)
7.16.5 Alvogen Key News & Latest Developments
7.17 Glenmark
7.17.1 Glenmark Company Summary
7.17.2 Glenmark Business Overview
7.17.3 Glenmark Cancer Generics Major Product Offerings
7.17.4 Glenmark Cancer Generics Revenue in Global Market (2018-2023)
7.17.5 Glenmark Key News & Latest Developments
7.18 HBT Labs
7.18.1 HBT Labs Company Summary
7.18.2 HBT Labs Business Overview
7.18.3 HBT Labs Cancer Generics Major Product Offerings
7.18.4 HBT Labs Cancer Generics Revenue in Global Market (2018-2023)
7.18.5 HBT Labs Key News & Latest Developments
7.19 Gland
7.19.1 Gland Company Summary
7.19.2 Gland Business Overview
7.19.3 Gland Cancer Generics Major Product Offerings
7.19.4 Gland Cancer Generics Revenue in Global Market (2018-2023)
7.19.5 Gland Key News & Latest Developments
7.20 Qilu Pharmaceuticals
7.20.1 Qilu Pharmaceuticals Company Summary
7.20.2 Qilu Pharmaceuticals Business Overview
7.20.3 Qilu Pharmaceuticals Cancer Generics Major Product Offerings
7.20.4 Qilu Pharmaceuticals Cancer Generics Revenue in Global Market (2018-2023)
7.20.5 Qilu Pharmaceuticals Key News & Latest Developments
7.21 Akorn Pharmaceuticals
7.21.1 Akorn Pharmaceuticals Company Summary
7.21.2 Akorn Pharmaceuticals Business Overview
7.21.3 Akorn Pharmaceuticals Cancer Generics Major Product Offerings
7.21.4 Akorn Pharmaceuticals Cancer Generics Revenue in Global Market (2018-2023)
7.21.5 Akorn Pharmaceuticals Key News & Latest Developments
7.22 MSN Group
7.22.1 MSN Group Company Summary
7.22.2 MSN Group Business Overview
7.22.3 MSN Group Cancer Generics Major Product Offerings
7.22.4 MSN Group Cancer Generics Revenue in Global Market (2018-2023)
7.22.5 MSN Group Key News & Latest Developments
7.23 Wockhardt
7.23.1 Wockhardt Company Summary
7.23.2 Wockhardt Business Overview
7.23.3 Wockhardt Cancer Generics Major Product Offerings
7.23.4 Wockhardt Cancer Generics Revenue in Global Market (2018-2023)
7.23.5 Wockhardt Key News & Latest Developments
7.24 Rising Pharma
7.24.1 Rising Pharma Company Summary
7.24.2 Rising Pharma Business Overview
7.24.3 Rising Pharma Cancer Generics Major Product Offerings
7.24.4 Rising Pharma Cancer Generics Revenue in Global Market (2018-2023)
7.24.5 Rising Pharma Key News & Latest Developments
7.25 Apotex
7.25.1 Apotex Company Summary
7.25.2 Apotex Business Overview
7.25.3 Apotex Cancer Generics Major Product Offerings
7.25.4 Apotex Cancer Generics Revenue in Global Market (2018-2023)
7.25.5 Apotex Key News & Latest Developments
7.26 Taro Pharmaceuticals
7.26.1 Taro Pharmaceuticals Company Summary
7.26.2 Taro Pharmaceuticals Business Overview
7.26.3 Taro Pharmaceuticals Cancer Generics Major Product Offerings
7.26.4 Taro Pharmaceuticals Cancer Generics Revenue in Global Market (2018-2023)
7.26.5 Taro Pharmaceuticals Key News & Latest Developments
7.27 Sun Pharma
7.27.1 Sun Pharma Company Summary
7.27.2 Sun Pharma Business Overview
7.27.3 Sun Pharma Cancer Generics Major Product Offerings
7.27.4 Sun Pharma Cancer Generics Revenue in Global Market (2018-2023)
7.27.5 Sun Pharma Key News & Latest Developments
7.28 Alkem Laboratories
7.28.1 Alkem Laboratories Company Summary
7.28.2 Alkem Laboratories Business Overview
7.28.3 Alkem Laboratories Cancer Generics Major Product Offerings
7.28.4 Alkem Laboratories Cancer Generics Revenue in Global Market (2018-2023)
7.28.5 Alkem Laboratories Key News & Latest Developments
7.29 Endo Pharma
7.29.1 Endo Pharma Company Summary
7.29.2 Endo Pharma Business Overview
7.29.3 Endo Pharma Cancer Generics Major Product Offerings
7.29.4 Endo Pharma Cancer Generics Revenue in Global Market (2018-2023)
7.29.5 Endo Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Cancer Generics Market Opportunities & Trends in Global Market
Table 2. Cancer Generics Market Drivers in Global Market
Table 3. Cancer Generics Market Restraints in Global Market
Table 4. Key Players of Cancer Generics in Global Market
Table 5. Top Cancer Generics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Cancer Generics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Cancer Generics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Cancer Generics Product Type
Table 9. List of Global Tier 1 Cancer Generics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cancer Generics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Cancer Generics Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Cancer Generics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Cancer Generics Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Cancer Generics Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Cancer Generics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Cancer Generics Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Cancer Generics Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Cancer Generics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Cancer Generics Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Cancer Generics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Cancer Generics Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Cancer Generics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Cancer Generics Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Cancer Generics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Cancer Generics Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Cancer Generics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Cancer Generics Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Cancer Generics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Cancer Generics Revenue, (US$, Mn), 2024-2032
Table 30. Teva Pharmaceuticals Company Summary
Table 31. Teva Pharmaceuticals Cancer Generics Product Offerings
Table 32. Teva Pharmaceuticals Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 33. Teva Pharmaceuticals Key News & Latest Developments
Table 34. Pfizer Company Summary
Table 35. Pfizer Cancer Generics Product Offerings
Table 36. Pfizer Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 37. Pfizer Key News & Latest Developments
Table 38. Accord Healthcare Company Summary
Table 39. Accord Healthcare Cancer Generics Product Offerings
Table 40. Accord Healthcare Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 41. Accord Healthcare Key News & Latest Developments
Table 42. Amneal Pharmaceuticals Company Summary
Table 43. Amneal Pharmaceuticals Cancer Generics Product Offerings
Table 44. Amneal Pharmaceuticals Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 45. Amneal Pharmaceuticals Key News & Latest Developments
Table 46. Mylan Company Summary
Table 47. Mylan Cancer Generics Product Offerings
Table 48. Mylan Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 49. Mylan Key News & Latest Developments
Table 50. DrReddy Laboratories Company Summary
Table 51. DrReddy Laboratories Cancer Generics Product Offerings
Table 52. DrReddy Laboratories Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 53. DrReddy Laboratories Key News & Latest Developments
Table 54. Bedford Pharma Company Summary
Table 55. Bedford Pharma Cancer Generics Product Offerings
Table 56. Bedford Pharma Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 57. Bedford Pharma Key News & Latest Developments
Table 58. Hikma Company Summary
Table 59. Hikma Cancer Generics Product Offerings
Table 60. Hikma Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 61. Hikma Key News & Latest Developments
Table 62. Cipla Company Summary
Table 63. Cipla Cancer Generics Product Offerings
Table 64. Cipla Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 65. Cipla Key News & Latest Developments
Table 66. Shilpa Medicare Company Summary
Table 67. Shilpa Medicare Cancer Generics Product Offerings
Table 68. Shilpa Medicare Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 69. Shilpa Medicare Key News & Latest Developments
Table 70. Fresenius Kabi Company Summary
Table 71. Fresenius Kabi Cancer Generics Product Offerings
Table 72. Fresenius Kabi Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 73. Fresenius Kabi Key News & Latest Developments
Table 74. Zydus Pharmaceuticals Company Summary
Table 75. Zydus Pharmaceuticals Cancer Generics Product Offerings
Table 76. Zydus Pharmaceuticals Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 77. Zydus Pharmaceuticals Key News & Latest Developments
Table 78. Neopharm Company Summary
Table 79. Neopharm Cancer Generics Product Offerings
Table 80. Neopharm Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 81. Neopharm Key News & Latest Developments
Table 82. Netco Company Summary
Table 83. Netco Cancer Generics Product Offerings
Table 84. Netco Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 85. Netco Key News & Latest Developments
Table 86. Mayne Pharma Company Summary
Table 87. Mayne Pharma Cancer Generics Product Offerings
Table 88. Mayne Pharma Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 89. Mayne Pharma Key News & Latest Developments
Table 90. Alvogen Company Summary
Table 91. Alvogen Cancer Generics Product Offerings
Table 92. Alvogen Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 93. Alvogen Key News & Latest Developments
Table 94. Glenmark Company Summary
Table 95. Glenmark Cancer Generics Product Offerings
Table 96. Glenmark Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 97. Glenmark Key News & Latest Developments
Table 98. HBT Labs Company Summary
Table 99. HBT Labs Cancer Generics Product Offerings
Table 100. HBT Labs Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 101. HBT Labs Key News & Latest Developments
Table 102. Gland Company Summary
Table 103. Gland Cancer Generics Product Offerings
Table 104. Gland Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 105. Gland Key News & Latest Developments
Table 106. Qilu Pharmaceuticals Company Summary
Table 107. Qilu Pharmaceuticals Cancer Generics Product Offerings
Table 108. Qilu Pharmaceuticals Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 109. Qilu Pharmaceuticals Key News & Latest Developments
Table 110. Akorn Pharmaceuticals Company Summary
Table 111. Akorn Pharmaceuticals Cancer Generics Product Offerings
Table 112. Akorn Pharmaceuticals Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 113. Akorn Pharmaceuticals Key News & Latest Developments
Table 114. MSN Group Company Summary
Table 115. MSN Group Cancer Generics Product Offerings
Table 116. MSN Group Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 117. MSN Group Key News & Latest Developments
Table 118. Wockhardt Company Summary
Table 119. Wockhardt Cancer Generics Product Offerings
Table 120. Wockhardt Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 121. Wockhardt Key News & Latest Developments
Table 122. Rising Pharma Company Summary
Table 123. Rising Pharma Cancer Generics Product Offerings
Table 124. Rising Pharma Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 125. Rising Pharma Key News & Latest Developments
Table 126. Apotex Company Summary
Table 127. Apotex Cancer Generics Product Offerings
Table 128. Apotex Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 129. Apotex Key News & Latest Developments
Table 130. Taro Pharmaceuticals Company Summary
Table 131. Taro Pharmaceuticals Cancer Generics Product Offerings
Table 132. Taro Pharmaceuticals Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 133. Taro Pharmaceuticals Key News & Latest Developments
Table 134. Sun Pharma Company Summary
Table 135. Sun Pharma Cancer Generics Product Offerings
Table 136. Sun Pharma Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 137. Sun Pharma Key News & Latest Developments
Table 138. Alkem Laboratories Company Summary
Table 139. Alkem Laboratories Cancer Generics Product Offerings
Table 140. Alkem Laboratories Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 141. Alkem Laboratories Key News & Latest Developments
Table 142. Endo Pharma Company Summary
Table 143. Endo Pharma Cancer Generics Product Offerings
Table 144. Endo Pharma Cancer Generics Revenue (US$, Mn) & (2018-2023)
Table 145. Endo Pharma Key News & Latest Developments
List of Figures
Figure 1. Cancer Generics Segment by Type in 2022
Figure 2. Cancer Generics Segment by Application in 2022
Figure 3. Global Cancer Generics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Cancer Generics Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Cancer Generics Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cancer Generics Revenue in 2022
Figure 8. By Type - Global Cancer Generics Revenue Market Share, 2018-2032
Figure 9. By Application - Global Cancer Generics Revenue Market Share, 2018-2032
Figure 10. By Type - Global Cancer Generics Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Cancer Generics Revenue Market Share, 2018-2032
Figure 12. By Application - Global Cancer Generics Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Cancer Generics Revenue Market Share, 2018-2032
Figure 14. By Region - Global Cancer Generics Revenue Market Share, 2018-2032
Figure 15. By Country - North America Cancer Generics Revenue Market Share, 2018-2032
Figure 16. US Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Cancer Generics Revenue Market Share, 2018-2032
Figure 20. Germany Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 21. France Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Cancer Generics Revenue Market Share, 2018-2032
Figure 28. China Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 32. India Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Cancer Generics Revenue Market Share, 2018-2032
Figure 34. Brazil Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Cancer Generics Revenue Market Share, 2018-2032
Figure 37. Turkey Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Cancer Generics Revenue, (US$, Mn), 2018-2032
Figure 41. Teva Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Pfizer Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Accord Healthcare Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Amneal Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Mylan Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. DrReddy Laboratories Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bedford Pharma Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Hikma Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Cipla Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Shilpa Medicare Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Fresenius Kabi Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Zydus Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Neopharm Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Netco Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Mayne Pharma Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Alvogen Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Glenmark Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. HBT Labs Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Gland Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Qilu Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 61. Akorn Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 62. MSN Group Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 63. Wockhardt Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 64. Rising Pharma Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 65. Apotex Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 66. Taro Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 67. Sun Pharma Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 68. Alkem Laboratories Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 69. Endo Pharma Cancer Generics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
